AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the signing of a purchase agreement for a state-of-the-art Cell and Gene Therapy commercial manufacturing facility in Longmont, Colorado, currently owned by Novartis Gene Therapies. Once the transaction closes, pending final due diligence, the facility will equip AGC Biologics with significant additional capacity and space to continue to expand its end-to-end Cell and Gene Therapy (C>) offering, ensuring security of supply for current and future C> customers. This facility is only 16 miles from AGC Biologics’ state-of-the-art large-scale stainless steel mammalian facility in Boulder, CO.
The Longmont facility fits perfectly into AGC’s long-term growth and expansion plans, says AGC Biologics Chief Executive Officer, Patricio Massera. This move is driven by our dedication to satisfy the needs of our current and future customers.